Chad Robins has shown notable fluctuations in his insider trading activities, once boasting a peak net worth of $164 million in September 2019. Since then, his stock values have varied, reflecting the company's performance and market changes. By 2023, the...

Chad Robins has shown notable fluctuations in his insider trading activities, once boasting a peak net worth of $164 million in September 2019. Since then, his stock values have varied, reflecting the company's performance and market changes. By 2023, the net estimated worth of his holdings dipped significantly but remained stable, averaging around $10 million. This illustrates Robins' ongoing commitment to Adaptive, where he not only leads but also invests substantially, aligning his financial interests with those of the shareholders. His holdings primarily consist of performance stock units, which tie directly to the company's operational success and overall market performance, emphasizing a strong, long-term incentive approach. The fluctuations in his stock values highlight the company's journey in the biotech sector and mirror key innovations and breakthroughs in medical technology.